Abstract
The insulin treatment represents a basic part in the care of patients with type 1 diabetes mellitus (DM), because autoimmune process leads to a gradual loss of beta cells of pancreatic islets with a decline of insulin secretion. The pathogenesis of type 2 diabetes mellitus is different, typically multifactorial, there are simultaneously present both qualitative and quantitative impairments of insulin secretion as well as a weakened incretin effect, influencing of which may be successfully used in the treatment.
The treatment with glucagon like peptide 1 (GLP-1) agonists has been currently approved for the treatment of type 2 diabetes mellitus only. Nevertheless, due to the effects of GLP-1 analogues outside the pancreatic beta cells, their use comes forward in type 1 diabetes mellitus as well.
Particularly in patients who are phenotypically similar to the patients with type 2 diabetes mellitus, those with overweight or obesity, insulin resistance and higher insulin consumption. The profit of liraglutide in type 1 diabetes mellitus is presented in the subsequent case report.